Core Viewpoint - Eason Technology Limited is currently not in compliance with NYSE American listing standards due to the failure to timely file its 2024 Form 20-F, which was due by May 15, 2025 [1][3]. Group 1: Compliance and Filing Status - The company received a notice from NYSE Regulation regarding its non-compliance with continued listing standards [1]. - The company is subject to a six-month Initial Cure Period until November 15, 2025, to rectify the Filing Delinquency [2]. - If the company fails to cure the delinquency within the Initial Cure Period, it may be granted an Additional Cure Period of up to six months, or face suspension and delisting procedures [2]. Group 2: Reasons for Filing Delay - The company cited delays in completing its financial statements for the period ended December 31, 2024, as the reason for not filing the 2024 Form 20-F on time [3]. - The company is making efforts to file the 2024 Form 20-F as soon as possible within the Initial Cure Period, but there is no assurance of regaining compliance [3]. Group 3: Impact on Trading - The delinquency notice does not have an immediate impact on the listing of the company's American Depositary Shares (ADSs), which will continue to be traded on NYSE American during the cure period [4]. Group 4: Company Overview - Eason Technology Limited is engaged in real estate operation management and investment, as well as digital technology security business in Hong Kong, China [5].

CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for ...